Pacylex Will Present Phase 1 Clinical Experience with PCLX-001 and Rationale for Expanding into Acute Myeloid Leukemia Patients at ASH 2022

2022-11-03

孤儿药First in Class小分子药物

Edmonton, Alberta--(News - November 3, 2022) - Pacylex today announced that data from the ongoing Phase 1 dose escalation clinical trial of PCLX-001, an N-myristoyltransferase (NMT) inhibitor, as well as the scientific rationale for its use in acute myeloid leukemia (AML) patients, will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition from 10-13 December 2022. The ongoing study is in Non-Hodgkin's Lymphoma and solid tumor patients and the company will present the non-clinical evidence that AML patients may benefit as well. To view the full announcement, including downloadable images, bios, and more, click here. Key Takeaways: Pacylex non-clinical data which strongly supports expanding clinical investigations of PCLX-001 to acute myeloid leukemia (AML) will be presented at the American Society of Hematology Annual Meeting. PCLX-001 safety experience in 17 lymphoma and solid tumor patients provides confidence to proceeding with a second clinical indication in AML. The company received FDA Orphan Drug Designation for PCLX-001 in AML and clearance of an IND to start dosing AML patients. Click image above to view full announcement. PCLX-001 PCLX-001 (aka DDD86481) is a first-in-class, small molecule NMT inhibitor originally developed by the University of Dundee Drug Discovery Unit as part of a program to treat African sleeping sickness, funded by Welcome Trust. Pacylex is developing PCLX-001 in the form of a once-a-day pill initially to treat leukemia and lymphoma. PCLX-001 has also been shown to inhibit the growth of lung and breast cancer tumors in animal models. In leukemia, lymphoma and breast cancer patients, the levels of NMT2 is correlated with survival, suggesting an important biological role in these cancers. About Pacylex Pacylex is a pharmaceutical company headquartered in Edmonton, Alberta, Canada, targeting hematologic and solid cancers with a new first-in-class therapeutic, PCLX-001. Pacylex's technology combines new insights from Dr. Luc Berthiaume of the University of Alberta connecting myristoylation to cancer with a family of high quality myristoylation inhibitors Pacylex licensed from the University of Dundee. PCLX-001 is the lead drug in a new class of NMT inhibitors, enabling Pacylex to exploit NMTs as new clinical targets for cancer treatment. Pacylex initiated clinical studies in Canada in the fall of 2021 in non-Hodgkin lymphoma and solid tumors and will soon initiate clinical studies in the US in acute myeloid leukemia patients. Pacylex is also receiving support from an Alberta Innovates AICE grant in 2020, and the research leading to this breakthrough was supported in part by the Alberta Cancer Foundation and the Cure Cancer Foundation. The US Department of Defense is supporting the initial clinical investigation of PCLX-001 in AML patients. For more information: Pacylex Pharmaceuticals Contact: Michael J. Weickert CEO, Pacylex Pharmaceuticals, Inc. E: michael.weickert@pacylex.com P: 650-218-1840 Twitter @Pacylex ( ) LinkedIn ( ) Facebook ( ) Reportable page: ( ) #cancer, #lymphoma, #leukemia, #albertacancer, #Pacylex, #PCLX001, #UAlberta; #UAlberta_FoMD; #Worldslongestgame, #ASH22 Contacts: Michael Weickert Ph.D 650-218-1840 michael.weickert@pacylex.com Source: Pacylex To view the source version of this press release, please visit

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构